About   Help   FAQ
Phenotypes associated with this allele
Allele Symbol
Allele Name
Allele ID 		Gt(ROSA)26Sortm10(Lmp1)Rsky
targeted mutation 10, Klaus Rajewsky
MGI:5314029
Summary 5 genotypes
Jump to Allelic Composition Genetic Background Genotype ID
cn1
 		Gt(ROSA)26Sortm10(Lmp1)Rsky/Gt(ROSA)26Sor+ involves: BALB/cJ MGI:5314102
cn2
 		Gt(ROSA)26Sortm10(Lmp1)Rsky/Gt(ROSA)26Sor+
Tcrbtm1Mom/Tcrb+
Tcrdtm1Mom/Tcrdtm1Mom
Cd19tm1(cre)Cgn/Cd19+ 		involves: 129P2/OlaHsd * 129S2/SvPas * BALB/cJ MGI:5314090
cn3
 		Gt(ROSA)26Sortm10(Lmp1)Rsky/Gt(ROSA)26Sor+
Tcrbtm1Mom/Tcrbtm1Mom
Tcrdtm1Mom/Tcrdtm1Mom
Cd19tm1(cre)Cgn/Cd19+ 		involves: 129P2/OlaHsd * 129S2/SvPas * BALB/cJ MGI:5314093
cn4
 		Gt(ROSA)26Sortm10(Lmp1)Rsky/Gt(ROSA)26Sor+
Cd19tm1(cre)Cgn/Cd19+ 		involves: 129P2/OlaHsd * BALB/cJ MGI:5314103
cn5
 		Gt(ROSA)26Sortm10(Lmp1)Rsky/Gt(ROSA)26Sor+
Klrk1tm1Dhr/Klrk1tm1Dhr
Cd19tm1(cre)Cgn/Cd19+ 		involves: 129P2/OlaHsd * BALB/cJ * C57BL/6 MGI:5314085


Genotype
MGI:5314102
cn1
Allelic
Composition		 Gt(ROSA)26Sortm10(Lmp1)Rsky/Gt(ROSA)26Sor+
Genetic
Background		 involves: BALB/cJ
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Gt(ROSA)26Sortm10(Lmp1)Rsky mutation (1 available); any Gt(ROSA)26Sor mutation (993 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype
immune system
increased B cell proliferation ( J:181546 )
• B cells treated with TAT-cre proliferate in culture unlike wild-type cells
abnormal B cell morphology ( J:181546 )
• B cells treated with TAT-cre exhibit increased cell size compared with wild-type cells

hematopoietic system
increased B cell proliferation ( J:181546 )
• B cells treated with TAT-cre proliferate in culture unlike wild-type cells
abnormal B cell morphology ( J:181546 )
• B cells treated with TAT-cre exhibit increased cell size compared with wild-type cells

cellular
increased B cell proliferation ( J:181546 )
• B cells treated with TAT-cre proliferate in culture unlike wild-type cells




Genotype
MGI:5314090
cn2
Allelic
Composition		 Gt(ROSA)26Sortm10(Lmp1)Rsky/Gt(ROSA)26Sor+
Tcrbtm1Mom/Tcrb+
Tcrdtm1Mom/Tcrdtm1Mom
Cd19tm1(cre)Cgn/Cd19+
Genetic
Background		 involves: 129P2/OlaHsd * 129S2/SvPas * BALB/cJ
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Cd19tm1(cre)Cgn mutation (11 available); any Cd19 mutation (60 available)
Gt(ROSA)26Sortm10(Lmp1)Rsky mutation (1 available); any Gt(ROSA)26Sor mutation (993 available)
Tcrbtm1Mom mutation (12 available); any Tcrb mutation (97 available)
Tcrdtm1Mom mutation (13 available); any Tcrd mutation (16 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype
mortality/aging

immune system

hematopoietic system

growth/size/body
enlarged spleen ( J:181546 )




Genotype
MGI:5314093
cn3
Allelic
Composition		 Gt(ROSA)26Sortm10(Lmp1)Rsky/Gt(ROSA)26Sor+
Tcrbtm1Mom/Tcrbtm1Mom
Tcrdtm1Mom/Tcrdtm1Mom
Cd19tm1(cre)Cgn/Cd19+
Genetic
Background		 involves: 129P2/OlaHsd * 129S2/SvPas * BALB/cJ
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Cd19tm1(cre)Cgn mutation (11 available); any Cd19 mutation (60 available)
Gt(ROSA)26Sortm10(Lmp1)Rsky mutation (1 available); any Gt(ROSA)26Sor mutation (993 available)
Tcrbtm1Mom mutation (12 available); any Tcrb mutation (97 available)
Tcrdtm1Mom mutation (13 available); any Tcrd mutation (16 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype
mortality/aging

immune system

liver/biliary system
enlarged liver ( J:181546 )
• occasionally

neoplasm
increased B cell derived lymphoma incidence ( J:181546 )
• most tumors resemble diffuse large B cell lymphomas (in 6 of 9 mice)

hematopoietic system

growth/size/body
enlarged liver ( J:181546 )
• occasionally
enlarged spleen ( J:181546 )




Genotype
MGI:5314103
cn4
Allelic
Composition		 Gt(ROSA)26Sortm10(Lmp1)Rsky/Gt(ROSA)26Sor+
Cd19tm1(cre)Cgn/Cd19+
Genetic
Background		 involves: 129P2/OlaHsd * BALB/cJ
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Cd19tm1(cre)Cgn mutation (11 available); any Cd19 mutation (60 available)
Gt(ROSA)26Sortm10(Lmp1)Rsky mutation (1 available); any Gt(ROSA)26Sor mutation (993 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype
mortality/aging
increased susceptibility to induced morbidity/mortality ( J:181546 )
• 2 weeks after treatment with a cocktail of depleting antibodies (anti-CD4, anti-CD8 and anti-Thy1)

immune system
enlarged spleen ( J:181546 )
• 2 weeks after treatment with a cocktail of depleting antibodies (anti-CD4, anti-CD8 and anti-Thy1)
abnormal B cell differentiation ( J:181546 )
• impaired in the bone marrow
increased pro-B cell number ( J:181546 )
• at 6 to 12 weeks in the bone marrow
decreased B cell number ( J:181546 )
• at 6 to 12 weeks in the spleen and bone marrow
• absent CD19+Fas+ B cells at 8 to 11 weeks in the spleen
decreased mature B cell number ( J:181546 )
• at 6 to 12 weeks in the bone marrow
decreased pre-B cell number ( J:181546 )
• at 6 to 12 weeks in the bone marrow
increased B cell number ( J:181546 )
• at P8, mice exhibit an increase in CD19+ B cells in the spleen compared with control mice
increased CD4-positive, alpha-beta T cell number ( J:181546 )
• at P8, but not P3, in the spleen
• of activated T cells in the bone marrow at 6 to 12 weeks
increased CD8-positive, alpha-beta T cell number ( J:181546 )
• at P8, but not P3, in the spleen
• of activated T cells in the bone marrow at 6 to 12 weeks
abnormal immune system physiology ( J:181546 )
• after 2 weeks, mice treated with a cocktail of depleting antibodies (anti-CD4, anti-CD8 and anti-Thy1) exhibit splenomegaly and become terminally ill unlike control mice
increased B cell proliferation ( J:181546 )
• after 2 weeks, mice treated with a cocktail of depleting antibodies (anti-CD4, anti-CD8 and anti-Thy1) exhibit rapid expansion of Lmp1+ B cell blasts largely confined to peripheral lymphoid organs and the bone marrow with some infiltration into the liver and rarely into lungs and kidneys compared with control mice
• however, mice treated with one depleting antibodies (anti-CD4, anti-CD8, anti-Thy1 or anti-CD4 and anti-CD8) do not exhibit expansion of B cells
abnormal CD8-positive, alpha-beta T cell physiology ( J:181546 )
• the CD8+ compartment of the bone marrow of mice treated with a cocktail of depleting antibodies (anti-CD4, anti-CD8 and anti-Thy1) exhibit a 2-fold increase in cells expressing IFN-gamma, TNF-alpha, IL4 and IL17

hematopoietic system
increased B cell proliferation ( J:181546 )
• after 2 weeks, mice treated with a cocktail of depleting antibodies (anti-CD4, anti-CD8 and anti-Thy1) exhibit rapid expansion of Lmp1+ B cell blasts largely confined to peripheral lymphoid organs and the bone marrow with some infiltration into the liver and rarely into lungs and kidneys compared with control mice
• however, mice treated with one depleting antibodies (anti-CD4, anti-CD8, anti-Thy1 or anti-CD4 and anti-CD8) do not exhibit expansion of B cells
enlarged spleen ( J:181546 )
• 2 weeks after treatment with a cocktail of depleting antibodies (anti-CD4, anti-CD8 and anti-Thy1)
abnormal B cell differentiation ( J:181546 )
• impaired in the bone marrow
increased pro-B cell number ( J:181546 )
• at 6 to 12 weeks in the bone marrow
decreased B cell number ( J:181546 )
• at 6 to 12 weeks in the spleen and bone marrow
• absent CD19+Fas+ B cells at 8 to 11 weeks in the spleen
decreased mature B cell number ( J:181546 )
• at 6 to 12 weeks in the bone marrow
decreased pre-B cell number ( J:181546 )
• at 6 to 12 weeks in the bone marrow
increased B cell number ( J:181546 )
• at P8, mice exhibit an increase in CD19+ B cells in the spleen compared with control mice
increased CD4-positive, alpha-beta T cell number ( J:181546 )
• at P8, but not P3, in the spleen
• of activated T cells in the bone marrow at 6 to 12 weeks
increased CD8-positive, alpha-beta T cell number ( J:181546 )
• at P8, but not P3, in the spleen
• of activated T cells in the bone marrow at 6 to 12 weeks
abnormal CD8-positive, alpha-beta T cell physiology ( J:181546 )
• the CD8+ compartment of the bone marrow of mice treated with a cocktail of depleting antibodies (anti-CD4, anti-CD8 and anti-Thy1) exhibit a 2-fold increase in cells expressing IFN-gamma, TNF-alpha, IL4 and IL17

cellular
increased B cell proliferation ( J:181546 )
• after 2 weeks, mice treated with a cocktail of depleting antibodies (anti-CD4, anti-CD8 and anti-Thy1) exhibit rapid expansion of Lmp1+ B cell blasts largely confined to peripheral lymphoid organs and the bone marrow with some infiltration into the liver and rarely into lungs and kidneys compared with control mice
• however, mice treated with one depleting antibodies (anti-CD4, anti-CD8, anti-Thy1 or anti-CD4 and anti-CD8) do not exhibit expansion of B cells

growth/size/body
enlarged spleen ( J:181546 )
• 2 weeks after treatment with a cocktail of depleting antibodies (anti-CD4, anti-CD8 and anti-Thy1)




Genotype
MGI:5314085
cn5
Allelic
Composition		 Gt(ROSA)26Sortm10(Lmp1)Rsky/Gt(ROSA)26Sor+
Klrk1tm1Dhr/Klrk1tm1Dhr
Cd19tm1(cre)Cgn/Cd19+
Genetic
Background		 involves: 129P2/OlaHsd * BALB/cJ * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Cd19tm1(cre)Cgn mutation (11 available); any Cd19 mutation (60 available)
Gt(ROSA)26Sortm10(Lmp1)Rsky mutation (1 available); any Gt(ROSA)26Sor mutation (993 available)
Klrk1tm1Dhr mutation (3 available); any Klrk1 mutation (27 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype
neoplasm
neoplasm ( J:181546 )
N
• mice are protected from Lmp1-driven lymphomagenesis




Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO)
Citing These Resources
Funding Information
Warranty Disclaimer, Privacy Notice, Licensing, & Copyright
Send questions and comments to User Support. 		last database update
12/10/2024
MGI 6.24 		The Jackson Laboratory